2025-04-14 21:14:46
Latest Post
IPO-bound Belrise Industries Ltd completes strategic acquisition of H-One India Private Limited
Mitsu Chem Plast Eyes ₹ 1,000 Cr Revenue by 2028
Aurobindo Pharma receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
NHPC Ltd commissions commercial operation of 107.14 MW of 300 MW Karnisar Solar Power Plant
Nureca Limited's Manufacturing Subsidiary Secures US FDA Registration
Stock Report
Gujarat Themis Biosyn Ltd Q2FY21 net profit surges to Rs. 11.34 crore
Posted On : 2020-11-10 16:11:24( TIMEZONE : IST )
GUJARAT THEMIS BIOSYN LTD. has reported financial results for the period ended September 30, 2020.
Financial Results (Q2 FY20-21) - QoQ Comparison
The company has reported total income of Rs.28.14 crores during the period ended September 30, 2020 as compared to Rs.16.52 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.11.34 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.5.57 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.7.81 for the period ended September 30, 2020 as compared to Rs.3.84 for the period ended June 30, 2020.
| Financials | Q2 FY20-21 | Q1 FY20-21 | % Change |
| Total Income | ₹ 28.14 crs | ₹ 16.52 crs |  70.34% |
| Net Profit | ₹ 11.34 crs | ₹ 5.57 crs | 103.59% |
| EPS | ₹ 7.81 | ₹ 3.84 | 103.39% |
Financial Results (Q2 FY20-21) - YoY Comparison
The company has reported total income of Rs.28.14 crores during the period ended September 30, 2020 as compared to Rs.17.01 crores during the period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.11.34 crores for the period ended September 30, 2020 as against net profit / (loss) of Rs.1.60 crores for the period ended September 30, 2019.
The company has reported EPS of Rs.7.81 for the period ended September 30, 2020 as compared to Rs.1.10 for the period ended September 30, 2019.
| Financials | Q2 FY20-21 | Q2 FY19-20 | % Change |
| Total Income | ₹ 28.14 crs | ₹ 17.01 crs | 65.43% |
| Net Profit | ₹ 11.34 crs | ₹ 1.60 crs | 608.75% |
| EPS | ₹ 7.81 | ₹ 1.10 | 610% |
Financial Results (6 months ended FY 20-21) - YoY Comparison
The company has reported total income of Rs.44.67 crores during the 6 months period ended September 30, 2020 as compared to Rs.29.42 crores during the 6 months period ended September 30, 2019.
The company has posted net profit / (loss) of Rs.16.91 crores for the 6 months period ended September 30, 2020 as against net profit / (loss) of Rs.3.01 crores for the 6 months period ended September 30, 2019.
The company has reported EPS of Rs.11.65 for the 6 months period ended September 30, 2020 as compared to Rs.2.08 for the 6 months period ended September 30, 2019.
| Financials | Half-Year Ended FY20-21 | Half-Year Ended FY19-20 | % Change |
| Total Income | ₹ 44.67 crs | ₹ 29.42 crs | 51.84% |
| Net Profit | ₹ 16.91 crs | ₹ 3.01 crs | 461.79% |
| EPS | ₹ 11.65 | ₹2.08 | 460.1% |
Shares of GUJARAT THEMIS BIOSYN LTD. was last trading in BSE at Rs.257.25 as compared to the previous close of Rs. 254.7. The total number of shares traded during the day was 37330 in over 454 trades.
The stock hit an intraday high of Rs. 263.25 and intraday low of 243. The net turnover during the day was Rs. 9554859.
